Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

REKHA JOHN

Allopathic & Osteopathic Physicians Internal Medicine Nephrology

NPI
1619979846
CMS profile
118220
Location
KINSTON, NC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2025 · Entire year

$388.84

15 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2025 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $387.18 14
Education $1.66 1

By paying entity

PY2025 · entire year · sorted by reported total

Page 1 of 1; records 1–15 of 15 matching records. This page contains 15 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

REKHA JOHN

NPI 1619979846 · CMS profile ID 118220

Allopathic & Osteopathic Physicians / Internal Medicine / Nephrology

KINSTON, NC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–15 of 15 matching records. This page contains 15 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1619979846?year=2025&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
REKHA JOHN, NPI 1619979846, CMS profile ID 118220. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–15 of 15 matching records. This page contains 15 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1619979846?year=2025&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
APA 7
IndustryPayments. (2026). REKHA JOHN, NPI 1619979846, CMS profile ID 118220. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–15 of 15 matching records. This page contains 15 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1619979846?year=2025&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
Bluebook
REKHA JOHN, NPI 1619979846, CMS profile ID 118220, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–15 of 15 matching records. This page contains 15 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1619979846?year=2025&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30

15 matching records · $388.84 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 15 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–15 of 15.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Novartis Pharmaceuticals Corporation $30.3312/02/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1200259903 CMS
Travere Therapeutics, Inc. $19.8511/13/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1244437951 CMS
Novo Nordisk Inc $26.2910/30/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1188408084 CMS
Novartis Pharmaceuticals Corporation $18.8210/27/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1200359250 CMS
SHIELD THERAPEUTICS INC $15.0210/15/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1249627224 CMS
Travere Therapeutics, Inc. $1.6610/14/2025 Education No dispute reported Delay: No
Change: NEW
06/30/2026 1244437949 CMS
Alexion Pharmaceuticals, Inc. $19.7109/03/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1202913308 CMS
Calliditas Therapeutics US Inc. $27.0208/22/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1234998663 CMS
Amgen Inc. $23.4707/24/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1228507615 CMS
Novartis Pharmaceuticals Corporation $32.2607/23/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1200359238 CMS
Amgen Inc. $24.8906/11/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1228507617 CMS
Fresenius USA Marketing, Inc. $18.4006/05/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1244819341 CMS
CorVista Health, Inc. $93.8104/17/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1250325732 CMS
Amgen Inc. $13.7204/08/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1227176924 CMS
Calliditas Therapeutics US Inc. $23.5904/01/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1234998661 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $77.93 6
PY2020 $119.67 2
PY2022 $404.00 18
PY2023 $539.51 20
PY2024 $2,789.07 18
PY2025 $388.84 15

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2022, 2023, 2024, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2020 , PY2022 , PY2023 , PY2024 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $499,069.81 26
PY2024 Principal investigator $549,482.70 50
PY2023 Principal investigator $376,752.37 57
PY2022 Recipient $7,645.61 7
PY2022 Principal investigator $353,881.30 372
PY2021 Principal investigator $168,644.86 191
PY2020 Principal investigator $154,822.49 45
PY2019 Principal investigator $231,281.89 292

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

50 records in PY2024

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $1,000.00 12/04/2024 Non-covered Recipient Entity
Interspond LLC
BAY 948862, A parallel-group treatment, Phase 2, double-blind, three-arm study to assess efficacy and safety of finerenone plus empagliflozin compared with either finerenone or empagliflozin in participants with chronic kidney disease and type 2 diabetes No dispute reported 06/30/2026 1156030160
Principal investigator 1 CSL Behring $484.30 11/27/2024 Non-covered Recipient Entity
Eastern Nephrology Associates
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1142326322
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $2,470.00 11/15/2024 Non-covered Recipient Entity
Interspond LLC
BAY 948862, A parallel-group treatment, Phase 2, double-blind, three-arm study to assess efficacy and safety of finerenone plus empagliflozin compared with either finerenone or empagliflozin in participants with chronic kidney disease and type 2 diabetes No dispute reported 06/30/2026 1156030162
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $500.00 11/13/2024 Non-covered Recipient Entity
Interspond LLC
BAY 948862, A parallel-group treatment, Phase 2, double-blind, three-arm study to assess efficacy and safety of finerenone plus empagliflozin compared with either finerenone or empagliflozin in participants with chronic kidney disease and type 2 diabetes No dispute reported 06/30/2026 1156030158
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $55.70 11/01/2024 Non-covered Recipient Entity
Interspond LLC
BAY 948862, A parallel-group treatment, Phase 2, double-blind, three-arm study to assess efficacy and safety of finerenone plus empagliflozin compared with either finerenone or empagliflozin in participants with chronic kidney disease and type 2 diabetes No dispute reported 06/30/2026 1156030176
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $55.37 10/25/2024 Non-covered Recipient Entity
Interspond LLC
BAY 948862, A parallel-group treatment, Phase 2, double-blind, three-arm study to assess efficacy and safety of finerenone plus empagliflozin compared with either finerenone or empagliflozin in participants with chronic kidney disease and type 2 diabetes No dispute reported 06/30/2026 1156030166
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $54.15 10/25/2024 Non-covered Recipient Entity
Interspond LLC
BAY 948862, A parallel-group treatment, Phase 2, double-blind, three-arm study to assess efficacy and safety of finerenone plus empagliflozin compared with either finerenone or empagliflozin in participants with chronic kidney disease and type 2 diabetes No dispute reported 06/30/2026 1156030172
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $1,863.00 10/23/2024 Non-covered Recipient Entity
Interspond LLC
BAY 948862, A parallel-group treatment, Phase 2, double-blind, three-arm study to assess efficacy and safety of finerenone plus empagliflozin compared with either finerenone or empagliflozin in participants with chronic kidney disease and type 2 diabetes No dispute reported 06/30/2026 1156030174
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $35.00 09/18/2024 Non-covered Recipient Entity
Interspond LLC
BAY 948862, A parallel-group treatment, Phase 2, double-blind, three-arm study to assess efficacy and safety of finerenone plus empagliflozin compared with either finerenone or empagliflozin in participants with chronic kidney disease and type 2 diabetes No dispute reported 06/30/2026 1156030156
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $210.00 09/18/2024 Non-covered Recipient Entity
Interspond LLC
BAY 948862, A parallel-group treatment, Phase 2, double-blind, three-arm study to assess efficacy and safety of finerenone plus empagliflozin compared with either finerenone or empagliflozin in participants with chronic kidney disease and type 2 diabetes No dispute reported 06/30/2026 1156030180
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $9,963.00 09/13/2024 Non-covered Recipient Entity
Interspond LLC
BAY 948862, A parallel-group treatment, Phase 2, double-blind, three-arm study to assess efficacy and safety of finerenone plus empagliflozin compared with either finerenone or empagliflozin in participants with chronic kidney disease and type 2 diabetes No dispute reported 06/30/2026 1156030150
Principal investigator 1 CSL Behring $31.08 09/09/2024 Non-covered Recipient Entity
Eastern Nephrology Associates
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1142326336
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $4,428.00 08/23/2024 Non-covered Recipient Entity
Interspond LLC
BAY 948862, A parallel-group treatment, Phase 2, double-blind, three-arm study to assess efficacy and safety of finerenone plus empagliflozin compared with either finerenone or empagliflozin in participants with chronic kidney disease and type 2 diabetes No dispute reported 06/30/2026 1156030164
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $1,415.00 08/14/2024 Non-covered Recipient Entity
Interspond LLC
BAY 948862, A parallel-group treatment, Phase 2, double-blind, three-arm study to assess efficacy and safety of finerenone plus empagliflozin compared with either finerenone or empagliflozin in participants with chronic kidney disease and type 2 diabetes No dispute reported 06/30/2026 1156030154
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $99.15 08/07/2024 Non-covered Recipient Entity
Interspond LLC
BAY 948862, A parallel-group treatment, Phase 2, double-blind, three-arm study to assess efficacy and safety of finerenone plus empagliflozin compared with either finerenone or empagliflozin in participants with chronic kidney disease and type 2 diabetes No dispute reported 06/30/2026 1156030168
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $60.17 08/07/2024 Non-covered Recipient Entity
Interspond LLC
BAY 948862, A parallel-group treatment, Phase 2, double-blind, three-arm study to assess efficacy and safety of finerenone plus empagliflozin compared with either finerenone or empagliflozin in participants with chronic kidney disease and type 2 diabetes No dispute reported 06/30/2026 1156030170
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $123.88 08/07/2024 Non-covered Recipient Entity
Interspond LLC
BAY 948862, A parallel-group treatment, Phase 2, double-blind, three-arm study to assess efficacy and safety of finerenone plus empagliflozin compared with either finerenone or empagliflozin in participants with chronic kidney disease and type 2 diabetes No dispute reported 06/30/2026 1156030182
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $372.00 08/07/2024 Non-covered Recipient Entity
Interspond LLC
BAY 948862, A parallel-group treatment, Phase 2, double-blind, three-arm study to assess efficacy and safety of finerenone plus empagliflozin compared with either finerenone or empagliflozin in participants with chronic kidney disease and type 2 diabetes No dispute reported 06/30/2026 1156030184
Principal investigator 1 CSL Behring $17.14 07/29/2024 Non-covered Recipient Entity
Eastern Nephrology Associates
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1142326292
Principal investigator 1 CSL Behring $1,955.43 07/17/2024 Non-covered Recipient Entity
Eastern Nephrology Associates
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1142326284
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $6,789.00 07/12/2024 Non-covered Recipient Entity
Interspond LLC
BAY 948862, A parallel-group treatment, Phase 2, double-blind, three-arm study to assess efficacy and safety of finerenone plus empagliflozin compared with either finerenone or empagliflozin in participants with chronic kidney disease and type 2 diabetes No dispute reported 06/30/2026 1156030178
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $1,500.00 07/10/2024 Non-covered Recipient Entity
Interspond LLC
BAY 948862, A parallel-group treatment, Phase 2, double-blind, three-arm study to assess efficacy and safety of finerenone plus empagliflozin compared with either finerenone or empagliflozin in participants with chronic kidney disease and type 2 diabetes No dispute reported 06/30/2026 1156030152
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $6,955.00 06/12/2024 Non-covered Recipient Entity
Interspond LLC
BAY 948862, A parallel-group treatment, Phase 2, double-blind, three-arm study to assess efficacy and safety of finerenone plus empagliflozin compared with either finerenone or empagliflozin in participants with chronic kidney disease and type 2 diabetes No dispute reported 06/30/2026 1085983364
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $83.61 05/08/2024 Non-covered Recipient Entity
Interspond LLC
BAY 948862, A parallel-group treatment, Phase 2, double-blind, three-arm study to assess efficacy and safety of finerenone plus empagliflozin compared with either finerenone or empagliflozin in participants with chronic kidney disease and type 2 diabetes No dispute reported 06/30/2026 1085983032
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $35.00 05/08/2024 Non-covered Recipient Entity
Interspond LLC
BAY 948862, A parallel-group treatment, Phase 2, double-blind, three-arm study to assess efficacy and safety of finerenone plus empagliflozin compared with either finerenone or empagliflozin in participants with chronic kidney disease and type 2 diabetes No dispute reported 06/30/2026 1085983362
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $150.00 05/01/2024 Non-covered Recipient Entity
Interspond LLC
BAY 948862, A parallel-group treatment, Phase 2, double-blind, three-arm study to assess efficacy and safety of finerenone plus empagliflozin compared with either finerenone or empagliflozin in participants with chronic kidney disease and type 2 diabetes No dispute reported 06/30/2026 1085982702
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $52.37 05/01/2024 Non-covered Recipient Entity
Interspond LLC
BAY 948862, A parallel-group treatment, Phase 2, double-blind, three-arm study to assess efficacy and safety of finerenone plus empagliflozin compared with either finerenone or empagliflozin in participants with chronic kidney disease and type 2 diabetes No dispute reported 06/30/2026 1085983030
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $231.99 05/01/2024 Non-covered Recipient Entity
Interspond LLC
BAY 948862, A parallel-group treatment, Phase 2, double-blind, three-arm study to assess efficacy and safety of finerenone plus empagliflozin compared with either finerenone or empagliflozin in participants with chronic kidney disease and type 2 diabetes No dispute reported 06/30/2026 1085983196
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $35.00 05/01/2024 Non-covered Recipient Entity
Interspond LLC
BAY 948862, A parallel-group treatment, Phase 2, double-blind, three-arm study to assess efficacy and safety of finerenone plus empagliflozin compared with either finerenone or empagliflozin in participants with chronic kidney disease and type 2 diabetes No dispute reported 06/30/2026 1085983360
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $1,476.00 04/05/2024 Non-covered Recipient Entity
Interspond LLC
BAY 948862, A parallel-group treatment, Phase 2, double-blind, three-arm study to assess efficacy and safety of finerenone plus empagliflozin compared with either finerenone or empagliflozin in participants with chronic kidney disease and type 2 diabetes No dispute reported 06/30/2026 1085982700
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $3,003.00 04/05/2024 Non-covered Recipient Entity
Interspond LLC
BAY 948862, A parallel-group treatment, Phase 2, double-blind, three-arm study to assess efficacy and safety of finerenone plus empagliflozin compared with either finerenone or empagliflozin in participants with chronic kidney disease and type 2 diabetes No dispute reported 06/30/2026 1085983198
Principal investigator 1 AstraZeneca Pharmaceuticals LP $34,812.49 03/20/2024 Non-covered Recipient Entity
MANUEL MONTERO
A Randomised Double-Blind Placebo-Controlled Parallel Group Study to Assess the Effect of Baxdrostat on Ambulatory Blood Pressure in Participants with Resistant Hypertension No dispute reported 06/30/2026 1110848125
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $150.00 03/13/2024 Non-covered Recipient Entity
Interspond LLC
BAY 948862, A parallel-group treatment, Phase 2, double-blind, three-arm study to assess efficacy and safety of finerenone plus empagliflozin compared with either finerenone or empagliflozin in participants with chronic kidney disease and type 2 diabetes No dispute reported 06/30/2026 1085983026
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $1,587.00 03/06/2024 Non-covered Recipient Entity
Interspond LLC
BAY 948862, A parallel-group treatment, Phase 2, double-blind, three-arm study to assess efficacy and safety of finerenone plus empagliflozin compared with either finerenone or empagliflozin in participants with chronic kidney disease and type 2 diabetes No dispute reported 06/30/2026 1085982860
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $35.00 02/28/2024 Non-covered Recipient Entity
Interspond LLC
BAY 948862, A parallel-group treatment, Phase 2, double-blind, three-arm study to assess efficacy and safety of finerenone plus empagliflozin compared with either finerenone or empagliflozin in participants with chronic kidney disease and type 2 diabetes No dispute reported 06/30/2026 1085983202
Principal investigator 1 AstraZeneca Pharmaceuticals LP $254,914.84 02/27/2024 Non-covered Recipient Entity
MANUEL MONTERO
A Phase III, Randomised, Multicentre, Double-blind Study to Evaluate the Efficacy, Safety and Tolerability of Zibotentan/Dapagliflozin FDC Compared to Dapagliflozin Alone in Participants with Chronic Kidney Disease and High Proteinuria No dispute reported 06/30/2026 1110846129
Principal investigator 1 VERTEX PHARMACEUTICALS INCORPORATED $15,392.95 02/16/2024 Non-covered Recipient Entity
EASTERN NEPHROLOGY ASSOCIATES KINSTON OFFICE
A Study of the Prevalance of Apolipoprotein L1 (APOL1) Alleles Among Individuals With Proteinuric Kidney Disease Who Are of Recent African Ancestry or Geographic Origin No dispute reported 06/30/2026 1095481700
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $400.00 02/14/2024 Non-covered Recipient Entity
Interspond LLC
BAY 948862, A parallel-group treatment, Phase 2, double-blind, three-arm study to assess efficacy and safety of finerenone plus empagliflozin compared with either finerenone or empagliflozin in participants with chronic kidney disease and type 2 diabetes No dispute reported 06/30/2026 1085982698
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $500.00 02/14/2024 Non-covered Recipient Entity
Interspond LLC
BAY 948862, A parallel-group treatment, Phase 2, double-blind, three-arm study to assess efficacy and safety of finerenone plus empagliflozin compared with either finerenone or empagliflozin in participants with chronic kidney disease and type 2 diabetes No dispute reported 06/30/2026 1085982864
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $194.00 02/14/2024 Non-covered Recipient Entity
Interspond LLC
BAY 948862, A parallel-group treatment, Phase 2, double-blind, three-arm study to assess efficacy and safety of finerenone plus empagliflozin compared with either finerenone or empagliflozin in participants with chronic kidney disease and type 2 diabetes No dispute reported 06/30/2026 1085983028
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $57.97 02/14/2024 Non-covered Recipient Entity
Interspond LLC
BAY 948862, A parallel-group treatment, Phase 2, double-blind, three-arm study to assess efficacy and safety of finerenone plus empagliflozin compared with either finerenone or empagliflozin in participants with chronic kidney disease and type 2 diabetes No dispute reported 06/30/2026 1085983200
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $1,305.00 02/07/2024 Non-covered Recipient Entity
Interspond LLC
BAY 948862, A parallel-group treatment, Phase 2, double-blind, three-arm study to assess efficacy and safety of finerenone plus empagliflozin compared with either finerenone or empagliflozin in participants with chronic kidney disease and type 2 diabetes No dispute reported 06/30/2026 1085983204
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $248.00 01/24/2024 Non-covered Recipient Entity
Interspond LLC
BAY 948862, A parallel-group treatment, Phase 2, double-blind, three-arm study to assess efficacy and safety of finerenone plus empagliflozin compared with either finerenone or empagliflozin in participants with chronic kidney disease and type 2 diabetes No dispute reported 06/30/2026 1085982696
Principal investigator 1 AstraZeneca Pharmaceuticals LP $42,036.00 01/19/2024 Non-covered Recipient Entity
MANUEL MONTERO
The purpose of the D4325C00007 study is to identify and characterise patients with known or newly diagnosed CKD for possible participation in future renal clinical studies and to obtain an overview on current treatment choices for this patient group in different regions No dispute reported 06/30/2026 1110836467
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $315.00 01/17/2024 Non-covered Recipient Entity
Interspond LLC
BAY 948862, A parallel-group treatment, Phase 2, double-blind, three-arm study to assess efficacy and safety of finerenone plus empagliflozin compared with either finerenone or empagliflozin in participants with chronic kidney disease and type 2 diabetes No dispute reported 06/30/2026 1085982866
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $35.00 01/12/2024 Non-covered Recipient Entity
Interspond LLC
BAY 948862, A parallel-group treatment, Phase 2, double-blind, three-arm study to assess efficacy and safety of finerenone plus empagliflozin compared with either finerenone or empagliflozin in participants with chronic kidney disease and type 2 diabetes No dispute reported 06/30/2026 1085982858
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $104.61 01/12/2024 Non-covered Recipient Entity
Interspond LLC
BAY 948862, A parallel-group treatment, Phase 2, double-blind, three-arm study to assess efficacy and safety of finerenone plus empagliflozin compared with either finerenone or empagliflozin in participants with chronic kidney disease and type 2 diabetes No dispute reported 06/30/2026 1085982862
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $35.00 01/12/2024 Non-covered Recipient Entity
Interspond LLC
BAY 948862, A parallel-group treatment, Phase 2, double-blind, three-arm study to assess efficacy and safety of finerenone plus empagliflozin compared with either finerenone or empagliflozin in participants with chronic kidney disease and type 2 diabetes No dispute reported 06/30/2026 1085983034
Principal investigator 1 AstraZeneca Pharmaceuticals LP $21,099.09 01/02/2024 Non-covered Recipient Entity
EASTERN NEPHROLOGY ASSOCIATES
A Randomized, Double Blind, Placebo Controlled, Multicenter, Parallel Group, Dose Ranging Study to Evaluate CIN 107 for the Treatment of Patients With Uncontrolled Hypertension and Chronic Kidney Disease No dispute reported 06/30/2026 1110845014
Principal investigator 1 VERTEX PHARMACEUTICALS INCORPORATED $130,757.41 01/01/2024 Non-covered Recipient Entity
EASTERN NEPHROLOGY ASSOCIATES KINSTON OFFICE
A Phase 2/3 Adaptive, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of VX-147 in Subjects Aged 18 Years and Older With APOL1-mediated Proteinuric Kidney Disease No dispute reported 06/30/2026 1095481084